The US Food and Drug Administration (FDA) has approved Exelixis’ Cabometyx (cabozantinib) to treat advanced neuroendocrine ...

Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO® in MET-high lung cancer, representing a ...

OS for osimertinib vs placebo was 58.8 vs 54 months at the latest analysis of the phase 3 LAURA trial, according to ...

DelveInsight’s, “Colorectal Cancer Pipeline Insight 2025” report provides comprehensive insights about 195+ companies and ...

In just over a year since its US Food and Drug Administration (FDA) approval, pirtobrutinib (Jayprica) has become a standard ...

Hoth Therapeutics announces positive preclinical results for HT-KIT in aggressive cancer gastrointestinal stromal tumours: New York Wednesday, March 19, 2025, 18:00 Hrs [IST] Hoth ...

Reports revenue RMB 980.7M vs. RMB 221.9M last year. Dajun Yang, CEO, said, “As we reflect on our achievements in 2024, I am delighted to ...

StockNews.com started coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Free Report) in a research note published on Thursday. The brokerage issued a hold rating on the stock. Oncternal ...

Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with previously treated advanced neuroendocrine tumors ...